



Is there FREEDOM to Perform PCI in Diabetic Patients with Multivessel Disease?

Malcolm R. Bell, MBBS, FRACP
Torino, IT
September 2013


Conflicts and disclosures - none

European Forecast for 2030:

Prevalence of Diabetes Mellitus
9.5% of adults
= 64 million patients

Clinical case

- 75 yr old woman with recent onset angina
- Risk factors:
 - DM2 5 years on metformin
 - Dyslipidemia on atorvastatin
 - HT on lisinopril
- CrCl = 49ml/min
- TMET: 3 minutes (angina and ST depression)
 - Duke score -15 (high risk)
- Resting Echo: LVEF 60% with no RWMA



SYNTAX Score = 17
EuroSCORE = 2.15%
STS score = 1%
(9.3% mortality or morbidity)

What would you recommend?

Diabetes and Revascularization of CAD

- Multivessel disease in USA
 - 700,000 pts revascularization per year
 - 25% have diabetes mellitus
- First BARI trial – preference for CABG over PCI
- Subsequent, but *old* trials (BARI-2D, CARDia) and subset of SYNTAX
 - CABG superior
- FREEDOM trial – contemporary practice
 - CABG superior to PCI

BARI 2D Trial – Key findings at 5 years

Med therapy equivalent to revascularization:
Survival (Primary)
Death, MI or CVA (Secondary)

CABG Stratum
CABG superior to med therapy
only for secondary end point

PCI Stratum
PCI equivalent to med therapy for both end points
-- DES 35%; Thienopyridines 21% --

BARI-2D Medical Therapy Groups

More frequent worsening or new angina

More revascularization
(half within 1st year)

SYNTAX Diabetes Group: 5-yr Results

Diabetes compared to no diabetes:


- Higher EuroSCORE
- Similar SYNTAX score
- More lesions treated; smaller vessels

PCI compared to CABG:

More MACCE + repeat revascularization

Death/MI/CVA not significantly different


Disease Complexity and Outcome among Diabetic Patients in SYNTAX Trial



Kappetein AP: Eur J Cardio-Thoracic Surg 2013

FREEDOM Trial

Primary End Point




No. at risk

PCI	953	848	788	625	416	219
CABG	947	814	758	613	422	221

Farkouh ME: NEJM, 2012

FREEDOM Trial

Mortality




No. at risk

PCI	953	897	845	685	466	243
CABG	947	855	806	655	449	238

Farkouh ME: NEJM, 2012

Conclusion:

In carefully selected patients, CABG should be the preferred mode of revascularization for diabetic patients with multivessel disease



SYNTAX Score = 17
EuroSCORE = 2.15%
STS score = 1%
(9.3% mortality or morbidity)

Same Clinical Case – risk changed

- Prior TIAs – on ASA
- GFR = 30 ml/min (CKD Stage 3B)
- Echo: LVEF 30%

EuroSCORE II = 8%

STS score = 2.5% mortality

(19% mortality and morbidity)


Guidelines

Opinions
and biases



Trial data

Real world
(comorbidities)



Trial data

Opinion
and biases

Real world
(comorbidities)

Guidelines

Comorbidities

Elderly
Frailty
Chronic lung disease
CVA/TIA
CKD (Stage 3-5)
Bleeding risk
Low LVEF

The patient

What end points
are important?
CVA avoidance
Expectations
Preferences
formed - internet

Effective Heart Team

Physician
experience and
clinical judgment




Guidelines

Contemporary PCI

- Use of 2nd and 3rd generation DES
- FFR - functional SYNTAX score
- IVUS for optimal stent results
- Improved antiplatelet therapy


Is your patient getting the best CABG?

- 69-yr old woman with class III angina
- Diabetes mellitus
- Prior DES to RCA



Internal Mammary Use in CABG

STS Database – 541,368 patients



Women

35%


Non white

21%

14% Multiple Arterial Grafts in MVD

Mayo Clinic 1993-2009


MultArt Subgroups
n=1,187



10 and 15 yr survival better than LIMA/SVG

Locker C: Circ 2012

2013 ESC Guidelines



Montalescot G: EHJ 2013